Skip to main content

STORIES

Dr. Stephani Stancil Receives Grant for Project Whose Ultimate Goal Is Reducing Unintended Pregnancy in Adolescents and Young Adults Experiencing Homelessness

STORIES

Dr. Stephani Stancil Receives Grant for Project Whose Ultimate Goal Is Reducing Unintended Pregnancy in Adolescents and Young Adults Experiencing Homelessness

Headshot of Stephani L. Stancil, PhD, APRN
Stephani L. Stancil, PhD, APRN
Assistant Professor of Pediatrics, University of Missouri-Kansas City School of Medicine; Research Assistant Professor of Pediatrics, University of Kansas School of Medicine
Full Biography

Stephani Stancil, PhD, APRN Adolescent Medicine, was recently awarded a $383,165 Investigator Studies Program award from Organon. The grant will cover a two-year period for Stancil’s project titled “A prospective, quasi-experimental study to evaluate the feasibility of CHOICE-AYA for unintended pregnancy prevention in adolescents and young adults (AYA) experiencing homelessness.”

The study’s long-term goal is to reduce unintended pregnancy and promote reproductive autonomy in AYA experiencing homelessness. This program will adapt an evidence-based contraceptive counseling intervention to AYA experiencing homelessness and study the impact of the intervention on contraceptive use, continuation, and satisfaction by comparing long acting reversible contraception (LARC) to other methods in a specialized community care setting.

“Our work aims to reduce reproductive health disparities in AYA experiencing homelessness through increased access to reliable contraception with a community-informed intervention. Findings will inform best practices for AYA experiencing homelessness and provide foundational evidence for future studies focused on expanding care to other sites that serve this group,” said Dr. Stancil.

Organon is global women’s health company focused on improving the health of women throughout their lives. Committed to women’s everyday health needs, the company focuses on reproductive health, health issues that are unique to women, as well as conditions that disproportionately affect women in addition to Biosimilars and Established Brands.

Co-investigators on the project include William Adelman, MD, Emily Hurley, PhD, MPH, Melissa Miller, MD, and Hung-Wen Yeh, PhD, MS.